Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

BACKGROUND: Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase inhibitors, leading to poor prognosis. CML blasts have constitutive p65...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Zhongzheng, Jin, Yanli, Chen, Chun, Li, Juan, Cao, Qi, Pan, Jingxuan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893099/
https://www.ncbi.nlm.nih.gov/pubmed/20482842
http://dx.doi.org/10.1186/1476-4598-9-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893099/
https://www.ncbi.nlm.nih.gov/pubmed/20482842
http://dx.doi.org/10.1186/1476-4598-9-112

Ejemplares similares